<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03344653</url>
  </required_header>
  <id_info>
    <org_study_id>MDT17054RES007</org_study_id>
    <nct_id>NCT03344653</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients</brief_title>
  <acronym>Onyx ONE</acronym>
  <official_title>Onyx ONE Study; A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical safety and effectiveness of the
      Resolute Onyx stent in subjects deemed at high risk for bleeding and/or medically unsuitable
      for more than 1 month DAPT treatment receiving reduced duration (1 month) of DAPT following
      stent implantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center, blinded, randomized, controlled study enrolling eligible subjects at global centers. The enrollment period is anticipated to be approximately 14 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Subjects will be randomized at a 1:1 ratio to treatment with Resolute Onyx stent or the BioFreedom stent (control).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint: Cardiac Death, Myocardial Infarction, or Stent Thrombosis</measure>
    <time_frame>1 year post-procedure</time_frame>
    <description>Powered for non-inferiority against BioFreedom (control), is a composite of cardiac death, myocardial infarction and definite/probable stent thrombosis. The combined clinical outcome of cardiac death, MI or stent thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure</measure>
    <time_frame>2 year post-procedure</time_frame>
    <description>Defined as cardiac death, target vessel myocardial infarction (Q wave and non Q wave), or clinically driven target lesion revascularization(TLR) by percutaneous or surgical methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>2 year post-procedure</time_frame>
    <description>Attainment of &lt;30% residual stenosis by QCA (or &lt;20% by visual assessment) AND TIMI flow 3 after the procedure, using any percutaneous method without the occurrence of MACE during the hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death</measure>
    <time_frame>2 year post- procedure</time_frame>
    <description>All deaths including cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Cardiac Event</measure>
    <time_frame>2 year post- procedure</time_frame>
    <description>Major adverse cardiac event (MACE) defined as composite of death, myocardial infarction, or repeat target lesion revascularization (clinically driven) by percutaneous or surgical methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>2 year post-procedure</time_frame>
    <description>All myocardial infarction including Target Vessel Myocardial Infarction (TVMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure</measure>
    <time_frame>2 year post-procedure</time_frame>
    <description>Target vessel failure (TVF) defined as composite of cardiac death, target vessel myocardial infarction, or clinically-driven target vessel revascularization (TVR) by percutaneous or surgical methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization</measure>
    <time_frame>2 year post-procedure</time_frame>
    <description>All revascularizations (TLR, TVR and non-TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>2 year post-procedure</time_frame>
    <description>Stent thrombosis (per Academic Research Consortium (ARC) definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>2 year post-procedure</time_frame>
    <description>Bleeding per BARC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>2 year post-procedure</time_frame>
    <description>Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Success</measure>
    <time_frame>2 year post-procedure</time_frame>
    <description>The attainment of &lt;30% residual stenosis by QCA (or &lt; 20% by visual assessment) AND TIMI flow 3 after the procedure, using any percutaneous method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>2 year post-procedure</time_frame>
    <description>Attainment of &lt;30% residual stenosis by QCA (or &lt;20% by visual assessment) AND TIMI flow 3 after the procedure, using the assigned device only.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Resolute Onyx stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioFreedom stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System</intervention_name>
    <description>Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by 1 month DAPT</description>
    <arm_group_label>Resolute Onyx stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biosensors BioFreedom BA9 Drug Coated Coronary Stent</intervention_name>
    <description>Biosensors BioFreedom BA9 Drug Coated Coronary Stent Followed by 1 month DAPT</description>
    <arm_group_label>BioFreedom stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 75 years old

          -  Any prior documented intracerebral bleed

          -  Any documented stroke in the last 12 months

          -  Hospital admission for bleeding during the prior 12 months

          -  Non-skin cancer diagnosed or treated ≤3 years

          -  Planned surgery within the next 12 months

          -  Renal failure defined as: Creatinine clearance &lt;40 ml/min

          -  Thrombocytopenia (PLT &lt;100,000/mm3)

          -  Severe chronic liver disease defined as: subjects who have developed any of the
             following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice

        Exclusion Criteria:

          -  Pregnant and breastfeeding women

          -  Subjects requiring a planned PCI procedure after 1 month of index procedure

          -  Active bleeding at the time of inclusion

          -  Cardiogenic shock

          -  A known hypersensitivity or contraindication to aspirin, heparin and bivalirudin,
             P2Y12 inhibitors, mTOR inhibiting drugs such as zotarolimus, Biolimus A9 (or its
             derivatives), cobalt, nickel, platinum, iridium, chromium, molybdenum, polymer
             coatings (eg, BioLinx™), stainless steel (or other metal ions found in 316L stainless
             steel), zinc, or a sensitivity to contrast media, which cannot be adequately
             pre-medicated.

          -  PCI during the previous 6 months for a lesion other than the target lesion of the
             index procedure

          -  Participation in another clinical study within 12 months after index procedure

          -  Subjects with life expectancy of less than 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Windecker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern University Hospital, Bern, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azeem Latib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Raffaele Scientific Institute, Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elvin Kedhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isala Zwolle, Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>A Kaiser</last_name>
    <phone>(763) 514-4000</phone>
    <email>rs.dapt@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bundaberg Cardiology - Friendly Society Private Hospital</name>
      <address>
        <city>Bundaberg</city>
        <state>Queensland</state>
        <zip>4670</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Fox</last_name>
    </contact>
    <investigator>
      <last_name>Andre Conradie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pietsch</last_name>
    </contact>
    <investigator>
      <last_name>Darren Walters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adelaide Cardiology</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renae Deans</last_name>
    </contact>
    <investigator>
      <last_name>Charles Tie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivo Petrov</last_name>
    </contact>
    <investigator>
      <last_name>Ivo Petrov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Lai</last_name>
    </contact>
    <investigator>
      <last_name>Frankie Tam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galway University Hospitals - University Hospital Galway (UHG)</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maura Burke</last_name>
    </contact>
    <investigator>
      <last_name>Darren Mylotte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Bolognini Seriate - Ospedale Bolognini</name>
      <address>
        <city>Seriate</city>
        <state>Bergamo</state>
        <zip>24068</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Tespili</last_name>
    </contact>
    <investigator>
      <last_name>Maurizio Tespili</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele Scientific Institute</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azeem Latib</last_name>
    </contact>
    <investigator>
      <last_name>Azeem Latib</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Fabbiocchi</last_name>
    </contact>
    <investigator>
      <last_name>Franco Fabbiocchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Ho Hur</last_name>
    </contact>
    <investigator>
      <last_name>Seung-Ho Hur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Byeol Kim</last_name>
    </contact>
    <investigator>
      <last_name>Myung-Ho Jeong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Ho Chae</last_name>
    </contact>
    <investigator>
      <last_name>In-Ho Chae</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Mi Kim</last_name>
    </contact>
    <investigator>
      <last_name>Yangsoo Jang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Jiyun</last_name>
    </contact>
    <investigator>
      <last_name>Hyeon Cheol Gwon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul Saint Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ChunYoung Baek</last_name>
    </contact>
    <investigator>
      <last_name>Kiyuk Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JongSun Kim</last_name>
    </contact>
    <investigator>
      <last_name>Seung Jung Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junghan Yoon</last_name>
    </contact>
    <investigator>
      <last_name>Junghan Yoon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paula Stradina Kliniska universitates slimnica</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alona Grave</last_name>
    </contact>
    <investigator>
      <last_name>Andrejs Erglis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Hospital</name>
      <address>
        <city>Kota Kinabalu</city>
        <state>Sabah</state>
        <zip>88300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liew Houng Bang</last_name>
    </contact>
    <investigator>
      <last_name>Liew Houng Bang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarawak Heart Centre</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiong Kiam Ong</last_name>
    </contact>
    <investigator>
      <last_name>Tiong Kiam Ong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Serdang</name>
      <address>
        <city>Kajang</city>
        <state>Selangor Darul Ehsan</state>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Balvinder Kaur Jaginder Singh</last_name>
    </contact>
    <investigator>
      <last_name>Kahar Abdul Ghapar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Zwolle</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvin Kedhi</last_name>
    </contact>
    <investigator>
      <last_name>Elvin Kedhi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy Fish</last_name>
    </contact>
    <investigator>
      <last_name>Mark Webster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Low</last_name>
      <phone>+64 7 839 8899</phone>
    </contact>
    <investigator>
      <last_name>Sanjeevan Pasupati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cher Yi Wong</last_name>
    </contact>
    <investigator>
      <last_name>Koo Hui Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena See Peng Ong</last_name>
    </contact>
    <investigator>
      <last_name>Paul J.L. Ong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stredoslovensky Ustav Srdcovych a Cievnych Chorob a.s</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hudec</last_name>
    </contact>
    <investigator>
      <last_name>Martin Hudec</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Valles Garcia</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo Pinar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mária Belén de la Fuente Perdomo</last_name>
    </contact>
    <investigator>
      <last_name>Francisco Bosa Ojeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Ajo Ferrer</last_name>
    </contact>
    <investigator>
      <last_name>Vincente Mainar Tello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Guerrero</last_name>
    </contact>
    <investigator>
      <last_name>Ángel Cequier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ainara Albadalejo</last_name>
    </contact>
    <investigator>
      <last_name>Raul Moreno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gävle sjukhus</name>
      <address>
        <city>Gävle</city>
        <zip>801 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kastberg</last_name>
    </contact>
    <investigator>
      <last_name>Robert Kastberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elin Blomberg</last_name>
    </contact>
    <investigator>
      <last_name>Nils Witt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital in Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunilla Forstedt</last_name>
    </contact>
    <investigator>
      <last_name>Loghman Henareh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Västmanlands Sjukhus</name>
      <address>
        <city>Västerås</city>
        <zip>721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carina Andersson</last_name>
    </contact>
    <investigator>
      <last_name>Erik Diderholm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Örebro</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika Eriksson</last_name>
    </contact>
    <investigator>
      <last_name>Ole Fröbert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belinda Rif</last_name>
    </contact>
    <investigator>
      <last_name>Neal Uren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Hong Kong</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

